Chest CT versus RT-PCR for the Detection of COVID-19:

Systematic Review and Meta-analysis

Mohammad Karam[1], Sulaiman Althuwaikh[2], Mohammad Alazemi[3], Ahmad Abul[1], Amrit Hayre[1], Gavin Barlow[4]

[1] School of Medicine, University of Leeds, Leeds, UK

[2] School of Medicine, University of Glasgow, Glasgow, UK

[3] School of Medical Sciences, University of Manchester, Manchester, UK

[4] Experimental Medicine and Biomedicine, Hull York Medical School, University of York, York, UK

Corresponding Author:

Mohammad Karam

Address: Al-Firdous, Block 4, Street 1, Avenue 6, Al-Farwaniyah, State of Kuwait.

Phone: +965 9916272, +44 7480644489

Email: mhk130@outlook.com

Author's Contributions

Mohammad Karam contributed in acquisition, analysis and interpretation of data as well as the study concept, initial design and supervision of the study. Sulaiman Althuwaikh and Mohammad Alazemi were responsible for screening additional papers, assessing the quality of included studies and drafting the manuscript. Ahmad Abul and Amrit Hayre helped in collecting and analysing data as well as drafting the manuscript. Gavin Barlow was the lead supervisor for critically reviewing the project, including editing of manuscripts. All authors substantially contributed in the conceptualisation of the study and approved the final manuscript.

Abstract

Purpose

To compare the performance of chest computed tomography (CT) scan versus reverse transcription polymerase chain reaction (RT-PCR) in the initial diagnostic assessment of coronavirus disease 2019 (COVID-19) patients.

Methods

A systematic review and meta-analysis were performed as per the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. A search of electronic information was conducted to identify all relevant studies comparing the diagnostic performance of chest CT scan versus RT-PCR in COVID-19 suspected cases. Sensitivity, specificity and accuracy were primary outcome measures. Secondary outcome measures included other test performance characteristics, discrepant findings between both investigations and main chest CT findings. Random effects modelling was used for the analyses.

Results

Eight non-randomised retrospective studies enrolling 1910 patients were identified. Chest CT was more sensitive but less specific than RT-PCR. Accuracy was not statistically significantly different between chest CT and RT-PCR for the identification and exclusion of COVID-19 cases (Odds Ratio [OR] = 0.40, P = 0.15) in the context of hospitalised patients in a pandemic. Chest CT was shown to detect patients with false-negative RT-PCR results and true positives. Ground-glass opacities and consolidations were the most common chest CT manifestations.

Conclusions

Chest CT is not superior to RT-PCR for the initial detection of COVID-19 and has more false positives. It is likely to be useful in confirming COVID-19 in patients with a suspicious clinical presentation, but who have a false-negative SARS-CoV-2 RT-PCR test.

Keywords

COVID-19; CT; RT-PCR; Diagnosis

Key Points

- Chest computed tomography (CT) is more sensitive but less specific in detecting and excluding coronavirus disease 2019 (COVID-19) when compared to reverse transcription polymerase chain reaction (RT-PCR).
- Accuracy of chest CT is not significantly different from RT-PCR for COVID-19 cases.
- Chest CT can detect false-negative and true-positive RT-PCR cases.

Abbreviation List

Abbreviation	Stands for
RCT	Randomised Controlled Trial
CIs	Confidence Intervals
OR	Odds Ratio
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
AHRQ	Agency for Healthcare Research and Quality
RT-PCR	Reverse Transcription Polymerase Chain Reaction
COVID-19	Coronavirus Disease 2019
SARS	Severe Acute Respiratory Syndrome
MERS	Middle East Respiratory Syndrome
ARDS	Acute Respiratory Distress Syndrome

1. Introduction

In December 2019, Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) emerged from Wuhan city, Hubei province, China[1,2]. SARS-COV-2 is part of the Coronavirdae family that includes the common cold, Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). These viruses can cause Acute Respiratory Distress Syndrome (ARDS), bilateral pneumonia and pulmonary failure leading to mortality[3]. There is yet to be a highly effective pharmacological therapy identified for COVID-19, further highlighting the importance of early detection and isolation of COVID-19 patients to prevent the spread of the disease[4].

Reverse-transcription polymerase chain reaction (RT-PCR) tests are currently the gold standard diagnostic tool for COVID-19. RT-PCR assays can be performed on nasopharyngeal and/or oropharyngeal swabs, sputum, blood samples, body fluids, stool samples and bronchoalveolar lavage fluid[5]. RT-PCR is limited by its low sensitivity and associated relatively high number of false-negative results that can lead to the erroneous assumption that a patient who does actually have COVID-19 is not infectious, and thus leading to an undetected transmission risk in either the community or within an institutional setting[4].

CT has become a standard of care in the diagnosis and assessment of a variety of respiratory conditions, such as interstitial lung disease and lung cancer, and optimises the management process[6,7]. Although CT scans are not routinely used to diagnose ARDS, certain complications that appear relating to mechanical ventilation, including pneumonia, pneumothorax and emphysema, are sometimes identified by CT but not chest radiography[8]. In addition, CT imaging can be used to identify lung atelectasis due to poor positioning of the endotracheal tube as well as potentially directing ventilation to achieve optimal pressures and air recruitment[8]. This is important in relation to COVID-19 since patients in ICU require optimisation of ventilatory settings and it is increasingly recognised that prone ventilation appears favourable[9]. Nevertheless, in the clinical setting, the benefits of routine CT imaging must be weighed against the considerable practicalities and risks,

including that of infection transmission associated with transporting a patient from the intensive care unit, or elsewhere in the hospital, to the radiology department[8]. The Royal College of Radiologists does not recommend the use of CT-scanning as a diagnostic tool for COVID-19, as a negative CT finding does not rule out COVID-19 infection, except for when CT-scanning results can change the management course such as those who require emergency surgery[10]. Furthermore, both the American Society of Emergency Radiology and the Society of Thoracic Radiology advise against the use of CT-scanning as a diagnostic tool for COVID-19[11]. They also recommend restricting the use of CT-scanning for confirmed and the highly suspected cases of COVID-19 when scanning can help manage complications such as patients with lung abscess[11].

Given the recent non-randomised studies comparing chest CT and RT-RCR in detecting COVID-19 cases [4,12-18], there is a need for ongoing systematic reviews and meta-analyses. This study aimed to compare the outcomes of chest CT-scan versus RT-PCR for the diagnosis of COVID-19 by systematic review of comparative studies (i.e. studies that have directly compared the performance of the two tests in the same patient cohort).

2. Methods

A systematic review and meta-analysis were conducted as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines[19].

2.1. Eligibility criteria

All relevant studies comparing chest CT with RT-PCR in the diagnosis of patients with suspected COVID-19 were included[4,12-18]. Chest CT was the intervention group of interest and RT-PCR was the comparator. All patients were included irrespective of age, gender or co-morbidity status. Studies that did not compare the two tests directly within the same patient cohort were excluded. Studies enrolling only confirmed COVID-19 cases or studies performing chest CT for prognostic rather than diagnostic purposes were also excluded.

2.2. Primary Outcomes

Sensitivity, specificity and accuracy for the diagnosis of COVID-19 cases were the primary outcomes. Sensitivity (true positive rate) is the proportion of actual COVID-19 cases a test correctly identifies. Specificity (true negative rate) is the proportion of non-COVID-19 cases a test correctly identifies. Accuracy is the proportion (true positives and true negatives) of total cases examined a test correctly identifies.

2.3. Secondary Outcomes

The secondary outcomes were positive predictive value (in the event of a positive test the probability the patient is truly positive), negative predictive value (in the event of a negative test the probability the patient is truly negative), positive (PLR) and negative likelihood (NLR) ratios (respectively, the probability a person who has COVID-19 testing positive divided by the probability of a person who does not have COVID-19 testing positive [PLR] and the probability of a person who has COVID-19 testing negative divided by the probability of a person who does not have COVID-19 testing negative [NLR]) and discrepancy of findings between both investigations as well as main chest CT findings.

2.4.   Literature search strategy

Three authors independently searched online databases as well as pre-print servers for details of ongoing and unpublished studies. The electronic databases were the following: MEDLINE, EMBASE, EMCARE, CINAHL and the Cochrane Central Register of Controlled Trials (CENTRAL). The last search was run on 25th of May 2020. Thesaurus headings, search operators and limits in each of the above databases were adapted accordingly. In addition, World Health Organization International Clinical Trials Registry, ClinicalTrials.gov, ISRCTN Register and medRxiv were searched for ongoing and unpublished studies. No language restrictions were applied in our search strategies. The search terminologies included "COVID-19", "Coronavirus", "SARS-CoV-2", "severe acute respiratory syndrome coronavirus 2", "CT", "computed tomography", "RT-PCR", "Reverse transcription polymerase chain reaction", "PCR" and "polymerase chain reaction". The bibliographic lists of relevant articles were also reviewed.

2.5.   Selection of Studies

The title and abstract of articles identified from the literature searches were assessed independently by two authors. The full texts of relevant reports were retrieved and those articles that met the eligibility criteria of our review were selected. Any discrepancies in study selection were resolved by discussion between the authors.

2.6.   Data Extraction and Management

An electronic data extraction spreadsheet using Microsoft Excel was created in line with Cochrane's data collection form for intervention reviews. The spreadsheet was pilot tested in randomly selected articles and adjusted accordingly. The data extraction spreadsheet included study-related data (first author, year of publication, country of origin of the corresponding author, journal in which the study was published, study design, study size, clinical condition of the study participants, type of intervention, and comparison), baseline demographics of the included populations (age and gender) and primary and secondary outcome data. Three authors

cooperatively collected and recorded the results and any disagreements were resolved via discussion.

2.7.   Data Synthesis

Data synthesis was conducted using the Review Manager 5.3 software and Microsoft Excel. The extracted data was entered into Review Manager by two independent authors. The analysis used was based on the random effect model. The results are reported in forest plots with 95% Confidence Intervals (CIs).

For dichotomous outcomes, the Odds Ratio (OR) was calculated between the 2 groups. The OR is the odds of an event in the chest CT group compared with the RT-PCR group. An OR of greater than 1 (with the lower 95% CI >1) for accuracy to detect or exclude COVID-19 cases favours Chest CT, an OR of less than 1 (with the upper 95% CI <1) favours RT-PCR, and an OR of 1 (with the 95% CIs bridging 1) favours neither. Pooled mean sensitivity and specificity values were generated. Summary receiver operator characteristic (sROC) curves were also generated with associated area under the receiver operating curves and 95% CIs.

Heterogeneity among the studies was assessed using the Cochran Q test (χ^2). Inconsistency was quantified by calculating I^2 and interpreted using the following guide: 0% to 25% may represent low heterogeneity, 25% to 75% may represent moderate heterogeneity, and 75% to 100% may represent high heterogeneity.

2.8.   Sensitivity and Subgroup Analyses

To identify areas of heterogeneity and assess the robustness of our results in studies with certain characteristics, additional sensitivity and sub-group analyses were performed.

2.9.   Methodological Quality and Risk of Bias Assessment

Two authors independently assessed the methodological quality as well as the risk of bias for articles matching the inclusion criteria. The Newcastle-Ottawa Scale[20] was used to assess the quality of included studies, which uses a star system for analyses. It offers a maximum score of nine

stars across three domains including selection, comparability and exposure. The overall rating of good, fair or poor quality was based on the Agency for Healthcare Research and Quality (AHRQ) standards[20]. A third author was used as an adjudicator if consensus was required.

3. Results

3.1. Literature Search Results

Our search strategy retrieved 944 studies. Eight studies met the eligibility criteria for inclusion following systematic review [4,12-18] (Figure 1).

3.2. Description of Studies:

The baseline characteristics of the included studies are summarised in Table 1. All included studies were comparative with CT scans being assessed using RT-PCR as the reference.

3.2.1. Ai et al. [4]

Ai et al.[4] conducted a single centre retrospective study that included 1014 patients (the largest study included) with suspected COVID-19 from January 6 to February 6, 2020. RT-PCR and chest CT results were obtained from medical records and three CT systems with all chest CT images reviewed by two radiologists.

3.2.2. Caruso et al. [12]

Caruso et al. conducted a single centre prospective cohort study that enrolled a total of 158 study participants that underwent both RT-PCR and chest CT due to COVID-19 suspicion from March 4, 2020 to March 19, 2020. Two experienced radiologists reviewed all chest CT images.

3.2.3. Fang et al. [13]

Fang et al.[13] performed a single centre retrospective study that included 51 patients with suspected COVID-19 from January 19 to February 4, 2020. All included patients underwent chest CT and RT-PCR testing within an interval of three days or less.

3.2.4. Gietema et al. [14]

Gietema et al. [14] conducted a single centre prospective study that included 193 symptomatic emergency department patients, who were suspected of having COVID-19, between March 13th and March 24th, 2020. All patients had a chest CT and RT-PCR test upon arrival to the emergency department. Data were collected from medical records and CT scan results compared to that of RT-PCR. The initial judgment of CT scans was performed by a senior resident and the final reading and reporting was performed by an experienced chest radiologist within 12 hours of scanning.

3.2.5. He et al. [15]

He et al. [15] performed a single centre retrospective study of 82 patients who were suspected to have COVID-19 between January 10th and February 28th, 2020. All patients underwent both RT-PCR and chest CT-scan testing. Interpretation and final diagnosis of the CT imaging was completed by two trained radiologists.

3.2.6. Long et al. [16]

Long et al.[16] performed a single centre retrospective study that included 87 patients with suspected COVID-19 patients between January 20th, 2020 and February 8th, 2020. All patients underwent a CT scan and RT-PCR. All lesions identified on chest CT images were predefined and reviewed by two radiologists.

3.2.7. Ma et al. [17]

Ma et al. [17] conducted a single centre retrospective study enlisting 158 children under the age of 17 who had a social or family exposure to COVID-19, from January 21st to February 14th, 2020. RT-PCR was initial performed with a follow up chest CT scan to evaluate lung pathology. Data was collected through access to patients' electronic medical records. CT scan results were assessed by two independent radiologists with at least a decade's worth of experience. If there was a discrepancy in the diagnosis from the CT scans, consensus was reached by discussion.

3.2.8.   Xie et al. [18]

Xie et al.[18] reported a single centre retrospective study that included 167 patients with high-risk COVID-19 cases. All available data, including clinical history, laboratory and epidemic characteristics, were collected. Two blinded radiologists independently reviewed the CT images.

3.3.   Primary Outcomes:

3.3.1.   Discriminatory power (sensitivity and specificity)

Sensitivity to detect COVID-19 cases was reported in eight studies enrolling 1910 patients [4, 12-18] (Figure 2). The sensitivity of CT and RT-PCR for the identification of COVID-19 cases was similar, with mean sensitivity values of 0.92 and 0.88 respectively (Table 2 and Table 3).

Specificity in identifying COVID-19 was reported in six studies enrolling 1692 patients [4,13] (Figure 2). The specificity for chest CT was lower than that of RT-PCR in the identification of COVID-19 cases, with mean specificity values of 0.70 and 1.00, respectively (Table 2 and Table 3).

Overall, CT and RT-PCR have similar discriminatory power in identifying patients with COVID-19 from non-infected patients (Figure 3).

3.3.2.   Diagnostic effectiveness (accuracy)

Accuracy to detect and exclude COVID-19 cases was reported in eight studies enrolling 1910 patients [4,12-18] (Figure 4). There was no statistically significant difference in the identification and exclusion of COVID-19 cases (OR = 0.40, CI = 0.12 to 1.39, P = 0.15), although the statistical trend favoured RT-PCR over CT. There was a high level of heterogeneity between studies (I^2 = 86%, P < 0.00001).

3.4. Secondary Outcomes:

3.4.1. Other test performance characteristics

Other test performance characteristics are summarised in Table 2 and Table 3. CT scan had a lower positive predictive value, calculated from all studies [4, 12-18], than RT-PCR, with mean values of 0.81 and 1.0 respectively. Conversely, the mean negative predictive value, calculated from Ai et al.[4] and Long et al.[16], was slightly higher for CT scan (0.91) versus RT-PCR (0.86). Additionally, the NLR, calculated from Ai et al.[4] and Long et al.[16], was lower for CT scan versus RT-PCR, with mean values of 0.14 and 0.22, respectively. Comparison between PCR and CT for PLR was impossible due to incomplete data.

3.4.2. Discrepancy of Findings

Ai et al.[4] (n = 1014) reported that 75% (n = 310) of patients with negative RT-PCR results and 97% (n = 583) of those with positive results had positive chest CT findings. Across all studies, only 5.1% (56/1051) of PCR positive patients had a negative CT scan (Table 4). 81% (42/52) of patients who initially had a negative PCR but then had a positive PCR later had a CT scan suggestive of COVID-19 (Table 4).

3.4.3. Main Chest CT Findings

According to Fang et al.[13] (n = 51), typical manifestations, such as peripheral, subpleural ground-glass opacities, usually in the lower lobes, were seen in 72% of detected cases by CT scan; atypical manifestations were found in 28% of cases. Caruso et al. [12] (n = 158) further highlighted that ground glass opacities (100%) with multi- (93%) and posterior (93%) lobe involvement, and bilateral distribution (91.4%) were the most common manifestations in COVID-19 cases confirmed by PCR. Similarly, Long et al.[16] (n = 87) found the commonest CT pattern in their cohort of COVID-19 cases was ground-glass opacities with consolidations (52.7%) in the lower lobes. Ma et al. [17] (n = 158) also reported that the most common manifestation was ground-glass opacities (58%). However, Ai et al.[4]

(n = 1014) found that consolidation and ground-glass opacities were reported in 50% and 46% of cases respectively.

3.5. Sensitivity Analyses

Sensitivity analyses were performed for the accuracy of CT scan and RT-PCR to identify and exclude COVID-19 cases. There was no change in the direction of the effect size and the overall heterogeneity when one study was removed at a time. However, when Fang et al. 2020 was removed the trend towards favouring of RT-PCR reached statistical significance. When the odds ratios, risk ratios and risk differences were calculated separately, there was no change in the direction of the effect size. There was similarly no change in the direction of the effect sizes when using the random or fixed effects models. Nevertheless, when using the fixed effect model, the trend towards favouring of R0T-PCR reached statistical significance.

3.6. Subgroup Analyses

3.6.1. China and Europe Based Studies

There was a statistically significant difference between China versus Europe-based subgroups in terms of accuracy in the identification of COVID-19 (P <0.0001); Figure 5. In China based studies there was no statistical difference between RT-PCR and CT scan (OR = 0.97, CI = 0.34 to 2.73, P = 0.95). In comparison, Europe based studies showed RT-PCR to be statistically significantly more accurate than CT (OR = 0.40, CI = 0.12 to 1.39, P < 0.0001).

3.6.2. Larger and Smaller Studies

There was also a statistically significant difference between larger (n ≥100) and smaller (n <100) study subgroups in accuracy for the identification COVID-19 (P = 0.01); Figure 6. Larger studies showed that RT-PCR is more accurate than CT scan with a statistically significant difference (OR = 0.08, CI = 0.01 to 0.57, P = 0.01). Smaller studies suggested no difference in accuracy between the two tests (OR = 3.90, CI = 0.38 to 40.45, P = 0.25).

3.6.3. Adult or Mixed Age and Children Based Studies

There was a statistically significant difference between adult or mixed age versus children-based subgroups in accuracy for the identification of COVID-19 (P = 0.01). Adult or mixed age-based studies suggested no difference in accuracy between RT-PCR and CT scan (OR = 0.60, CI = 0.18 to 1.97, P = 0.40). Children-based studies favoured PCR with statistical significance (OR = 0.01, CI = 0.00 to 0.19, P = 0.002).

3.7. Methodological Quality and Risk of Bias Assessment

Although comparability was low in all studies [4,12-18], selection and exposure were of higher quality (Table 5). Overall, all studies were of good quality based on the AHRQ standards [16].

4. Discussion:

Our findings suggest that chest CT performs similarly to RT-PCR in the initial detection of COVID-19 in the clinical context of the studies presented (i.e. hospitalised patients within a pandemic). CT had a slightly higher sensitivity (lower false negatives), but lower specificity (higher false positives) than RT-PCR. There was no statistical difference in the accuracy of CT when compared to RT-PCR for the identification and exclusion of COVID-19 cases (P = 0.15). The performance characteristics of all tests is context dependent, however, which means that the performance of CT for identifying COVID-19 will be different outside of a pandemic and in areas of the world with different endemicities. When the causes of bilateral CT changes return to the usual heterogeneous state, with SARS-CoV-2 only one of many potential causes, as was the situation pre-pandemic, the performance of CT will likely deteriorate with an even higher number of false positives, in keeping with the relatively modest PLR for CT, even within a pandemic setting, based on the study of Ai et al.[4] For patients requiring hospitalisation with an acute cardio-respiratory presentation, a negative CT scan will likely remain reassuring, particularly if RT-PCR is also negative

in keeping with the lower NLRs for CT versus RT-PCR. Our results cannot be extrapolated to healthier SARS-CoV-2 patient cohorts who are managed on an outpatient basis or in a community setting.

Diagnostic tests always have inherent strengths and weaknesses. In the case of the COVID-19 pandemic it would be preferable to have a simple test with high sensitivity leading to a low number of false negatives thereby allowing accurate decision-making regarding, for example, who may be infectious and requires isolation in the hospital setting or home isolation in the community. Based on those who had a suggestive CT but tested negative with RT-PCR, our findings suggest that CT scan may be able to detect a greater proportion of COVID-19 cases overall and may be useful when PCR testing is initially negative but clinical suspicion high [4]. There were relatively few patients who had a negative CT scan, but who were initially RT-PCR positive. Of the studies that reported patients who were initially RT-PCR negative, but subsequently became positive, 8 out of 10 patients had a suggestive CT. It is important to note that across the studies, however, only a small proportion who were initially RT-PCR negative were systematically retested.

Our results suggest that chest CT scan is not superior than RT-PCR in the initial detection of COVID-19, which supports published guidance and thus we do not advocate routine use. CT scans are subject to their inherent limitations. Firstly, they are best avoided during pregnancy due to the excessive radiation and risk of harming the foetus[21]. In addition, over-scanning patients with suspected COVID-19 can increase the risk of incidental imaging findings and an unnecessary financial burden on the healthcare system[22]. Furthermore, the use of CT-scans for suspected cases is not practical since SARS-CoV-2 has a relatively high transmission rate; each CT machine needs to be sterilised after use, which can waste time and resources as well as overworking the radiology department in times of need and hence may result in delayed reporting of other potentially life-threatening conditions. Lastly, with many countries having problems with providing their healthcare staff with sufficient personal protective equipment (PPE), sending suspected cases for a CT to confirm the diagnosis will unnecessarily consume PPE.

Given the above, and based on our results therefore, we suggest that chest CT is a useful supplementary diagnostic strategy for COVID-19 in patients with suspicious symptoms, but a negative RT-PCR test result. In such situations, a repeat upper respiratory tract RT-PCR, which is simple to do, rather than a CT scan is also worth considering, although in our clinical experience some patients with suspicious presentations are repeatedly negative or only positive on a third or fourth test. Lower respiratory tract specimens (i.e. sputum or bronchoalveolar lavage) are more likely to be positive, although most hospitalised patients are neither productive nor ventilated.

In the studies included, the most common manifestations of COVID-19 in chest CT scans were ground-glass opacities and consolidations [4, 12-13, 16-17]. Based on the evidence from previous coronavirus outbreaks, the use of CT-scans may have some clinical and prognostic importance. In MERS, lung radiographic changes such as ground-glass opacifications and consolidations tend to affect the lung bases and can be used as an independent prognostic factor; patients with pleural effusion or pneumothorax have a higher mortality risk[23,24]. Up to 30% of COVID-19 patients develop ARDS, which cannot always be confirmed on chest X-ray, making CT-scans potentially useful in such circumstances[25,26]. Comparing the imaging findings of COVID-19 to SARS, despite both having absent features of pleural effusion and lymphadenopathy, COVID-19 tends to cause consolidation in multiple lung zones versus SARS, which tends to cause unifocal involvement [4,27-28].

This review provides a summary of the best available evidence using a systematic approach and evaluated the risk of bias of included studies [4,12-18]. Although Kim et al.[29] recently published a meta-analysis on this topic, many of the studies included were not comparative (i.e. the tests were not compared within the same patient cohorts). Kim et al.[29] reported pooled sensitivity to be higher in CT scan (Sensitivity = 94%, 95% CI = 91% to 96%, I^2 = 95%) than RT-PCR (Sensitivity = 89%, 95% CI = 81% to 94%, I^2 = 83%), which supports our findings. Our study synthesised comparative studies only, and also included additional recently published studies and those in preprint, so our results may more accurately represent how the investigations can be expected to perform and compare in routine clinical practice. Our study also constructed summary receiver operator characteristic curves

that can overcome some of limitations of univariate pooled sensitivity and specificity analyses [30].

However, the reported outcomes should be considered in the context of the inherent limitations.

Only eight non-randomised studies were identified enrolling a total of 1910 participants, which may

not be enough to draw definite conclusions, and suggesting the need for further robust prospective

research. The performance of molecular tests for SARS-CoV-2 is likely to improve over time.

Likewise, the use of, for example, machine learning algorithms to interpret chest CT scan

appearances may more accurately confirm Covid-19 than human reporting in the future, and

thereby decrease the false-positive rate of CT scanning that can be expected to increase as the

pandemic wanes. Some included studies had incomplete data resulting in difficulty in comparing

both interventions completely. Additionally, all but one study included a relatively small number of

patients and the majority were of retrospective observational design, with all the associated caveats

of such studies. It is likely that further large comparative, and possibly prospective, studies will be

reported with further meta-analyses required. The between-study heterogeneity for outcomes was

high for sensitivity and accuracy. Based on the data presented in the studies included, zero false

positives with RT-PCR were assumed, which is unlikely to be the case in real-life, although published

studies do suggest false positives are rare.

5. Conclusions

Our study synthesised the best available comparative evidence, using a systematic approach,

for the identification of COVID-19 using RT-PCR versus chest CT[4,12-18]. Our results suggest that chest

CT scan is not superior to RT-PCR in the initial detection of COVID-19 in hospitalised patients in the

context of a pandemic. Because of the inherent limitations of CT, however, we suggest RT-PCR

remains the primary diagnostic tool, but that chest CT be considered if there is a strong clinical

suspicion of COVID-19 and a negative RT-PCR test result, providing infection prevention and control

measures can be maintained. A negative CT scan is likely to be reassuring in a RT-PCR negative

patient requiring hospitalisation for possible COVID-19.

6. References

1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KS, Lau EH, Wong JY, Xing X. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. New England Journal of Medicine. 2020 Jan 29.

2. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. International journal of antimicrobial agents. 2020 Feb 17:105924.

3. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research. 2020 Mar 16.

4. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020 Feb 26:200642.

5. China National Health Commission. Diagnosis and treatment of pneumonitis caused by new coronavirus (trial version 5). Beijing: China National Health Commission. 2020.

6. Walsh SL, Hansell DM. High-resolution CT of interstitial lung disease: a continuous evolution. InSeminars in respiratory and critical care medicine 2014 Feb (Vol. 35, No. 01, pp. 129-144). Thieme Medical Publishers.

7. Lee J, Sanchez TR, Zhang Y, Jhawar S. The role of high-resolution chest CT in the diagnosis of neuroendocrine cell hyperplasia of infancy–A rare form of pediatric interstitial lung disease. Respiratory medicine case reports. 2015 Jan 1;16:101-3.

8. Sheard S, Rao P, Devaraj A. Imaging of acute respiratory distress syndrome. Respiratory care. 2012 Apr 1;57(4):607-12.

9. Ghelichkhani P, Esmaeili M. Prone Position in Management of COVID-19 Patients; a Commentary. Archives of Academic Emergency Medicine. 2020;8(1).

10. Royal Collage of Radiologists. RCR Position on The Role Of CT In Patients Suspected With COVID-19 Infection | The Royal College Of Radiologists. Available from:

https://www.rcr.ac.uk/college/coronavirus-covid-19-what-rcr-doing/clinical-information/rcr-position-role-ct-patients [Accessed 25 April 2020].

11. Society of Thoracic Radiology. STR / ASER COVID-19 Position Statement March 11, 2020. Available from: https://thoracicrad.org/wp-content/uploads/2020/03/STR-ASER-Position-Statement-1.pdf [Accessed 25 April 2020].

12. Caruso D, Zerunian M, Polici M, Pucciarelli F, Polidori T, Rucci C, Guido G, Bracci B, de Dominicis C, Laghi A. Chest CT features of COVID-19 in Rome, Italy. Radiology. 2020 Apr 3:201237.

13. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, Ji W. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology. 2020 Feb 19:200432.

14. Gietema HA, Zelis N, Nobel JM, Lambriks LJ, van Alphen LB, Lashof AM, Wildberger JE, Nelissen IC, Stassen PM. CT in relation to RT-PCR in diagnosing COVID-19 in the Netherlands: a prospective study. medRxiv. 2020 Jan 1.

15. He JL, Luo L, Luo ZD, Lyu JX, Ng MY, Shen XP, Wen Z. Diagnostic performance between CT and initial real-time RT-PCR for clinically suspected 2019 coronavirus disease (COVID-19) patients outside Wuhan, China. Respiratory Medicine. 2020 Apr 21:105980.

16. Long C, Xu H, Shen Q, Zhang X, Fan B, Wang C, Zeng B, Li Z, Li X, Li H. Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT?. European Journal of Radiology. 2020 Mar 25:108961.

17. Ma H, Hu J, Tian J, Zhou X, Li H, Laws MT, Wesemann LD, Zhu B, Chen W, Ramos R, Xia J. A single-center, retrospective study of COVID-19 features in children: a descriptive investigation. BMC medicine. 2020 Dec;18:1-1.

18. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology. 2020 Feb 12:200343.

19. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of internal medicine. 2009 Aug 18;151(4):264-9.

20. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses (www.ohri.ca/programs/clinical_epidemiology/oxford.htm)

21. Goldberg-Stein S, Liu B, Hahn PF, Lee SI. Body CT during pregnancy: utilization trends, examination indications, and fetal radiation doses. American Journal of Roentgenology. 2011 Jan;196(1):146-51.

22. Coward J, Nightingale J, Hogg P. The clinical dilemma of incidental findings on the low-resolution CT images from SPECT/CT MPI studies. Journal of nuclear medicine technology. 2016 Sep 1;44(3):167-72.

23. Ajlan AM, Ahyad RA, Jamjoom LG, Alharthy A, Madani TA. Middle East respiratory syndrome coronavirus (MERS-CoV) infection: chest CT findings. American Journal of Roentgenology. 2014 Oct;203(4):782-7.

24. Colombi D, Bodini FC, Petrini M, Maffi G, Morelli N, Milanese G, Silva M, Sverzellati N, Michieletti E. Well-aerated Lung on Admitting Chest CT to Predict Adverse Outcome in COVID-19 Pneumonia. Radiology. 2020 Apr 17:201433.

25. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020 Feb 15;395(10223):497-506.

26. Gattinoni L, Caironi P, Valenza F, Carlesso E. The role of CT-scan studies for the diagnosis and therapy of acute respiratory distress syndrome. Clinics in chest medicine. 2006 Dec 1;27(4):559-70.

27. Wong KT, Antonio GE, Hui DS, Lee N, Yuen EH, Wu A, Leung CB, Rainer TH, Cameron P, Chung SS, Sung JJ. Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients. Radiology. 2003 Aug;228(2):401-6.

28. Das KM, Lee EY, Jawder SE, Enani MA, Singh R, Skakni L, Al-Nakshabandi N, AlDossari K, Larsson SG. Acute Middle East respiratory syndrome coronavirus: temporal lung changes observed on the chest radiographs of 55 patients. American Journal of Roentgenology. 2015 Sep;205(3):W267-S274.

29. Kim H, Hong H, Yoon SH. Diagnostic performance of CT and reverse transcriptase-polymerase chain reaction for coronavirus disease 2019: a meta-analysis. Radiology. 2020 Apr 17:201343.

30. Korsten MA. Application of summary receiver operating characteristics (sROC) analysis to diagnostic clinical testing. 7 Reflections on the future of gastroenterology–unmet needs. 2007;52:76.

Study	Journal or Preprint Server, Country	Study Design	Age [mean ± SD, median (range) years]	Sex (M:F)	Total Sample	Interventions Compared
Ai et al. (2020)	Radiology, China	Retrospective Study	51 ± 15, NR	547:467	1014	Chest CT versus RT-PCR
Caruso et al. (2020)	Radiology, Italy	Prospective Study	57 ± 17, NR	83:75	158	Chest CT versus RT-PCR
Fang et al. (2020)	Radiology, China	Retrospective Study	NR, 45	29:22	51	Chest CT versus RT-PCR
Gietema et al. (2020)	medRxiv, Netherlands	Prospective Study	NR, 66 (55-76)	113:80	193	Chest CT versus RT-PCR
He et al. (2020)	Respiratory medicine, China	Retrospective Study	COVID-19: NR, 52 (8-74) Non-COVID-19: NR, 37 (1-76)	49:35	82	Chest CT versus real-time RT-PCR
Long et al. (2020)	European Journal of Radiology, China	Retrospective Study	44.8 ± 18.2, NR	46:41	87	Chest CT versus real-time RT-PCR
Ma et al. (2020)	BMC Medicine, China	Retrospective Study	COVID-19: 2.5, NR (0.9-9.8) Non-COVID-19: NR	COVID-19: 54:34 Non-COVID-19: NR	158	Chest CT versus real-time RT-PCR
Xie et al. (2020)	Radiology, China	Retrospective Study	NR	NR	167	Chest CT versus RT-PCR

Table 1. Baseline Characteristics of the Included Studies.

Key NR: Not Reported.

Study ID	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Accuracy	PPV	NPV	PLR	NLR
Ai 2020	601	0*	250	163	0.71 [0.67, 0.74]	1.00 [0.98, 1.00]	0.75	1	0.39	Not estimable	0.29
Caruso 2020	62	0*	0	96	1.00 [0.94, 1.00]	1.00 [0.96, 1.00]	1	1	1	Not estimable	0
Fang 2020	36	0*	15	0	0.71 [0.56, 0.83]	Not estimable	0.70	1	0	Not estimable	Not estimable
Gietema 2020	83	0*	0	110	1.00 [0.96, 1.00]	1.00 [0.97, 1.00]	1	1	1	Not estimable	0
He 2020	27	0*	7	48	0.79 [0.62, 0.91]	1.00 [0.93, 1.00]	0.91	1	0.87	Not estimable	0.21
Long 2020	30	0*	6	51	0.83 [0.67, 0.94]	1.00 [0.93, 1.00]	0.93	1	0.89	Not estimable	0.17
Ma 2020	50	0*	0	108	1.00 [0.93, 1.00]	1.00 [0.97, 1.00]	1	1	1	Not estimable	0
Xie 2020	162	0*	5	0	0.97 [0.93, 0.99]	Not estimable	0.97	1	0	Not estimable	Not estimable
Mean values					0.88	1	0.91	1	0.86	Not estimable	0.22

Table 2. The performance of RT-PCR for COVID-19 infection. * Assumes no false positive due to non-reported data.

Key TP: True Positive, FP: False Positive, FN: False Negative, TN: True Negative, CI: Confidence Interval, PPV: Positive Predictive Value, NPV: Negative Predictive Value, PLR: Positive Likelihood Ratio, NLR: Negative Likelihood Ratio.

Study ID	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Accuracy	PPV	NPV	PLR	NLR
Ai 2020	580	308	21	105	0.97 [0.95, 0.98]	0.25 [0.21, 0.30]	0.68	0.65	0.83	1.29	0.14
Caruso 2020	60	42	2	54	0.97 [0.89, 1.00]	0.56 [0.46, 0.66]	0.72	0.59	0.96	2.21	0.06
Fang 2020	50	0*	1	0	0.98 [0.90, 1.00]	Not estimable	0.98	1	0	Not estimable	Not estimable
Gietema 2020	74	35	9	75	0.89 [0.80, 0.95]	0.68 [0.59, 0.77]	0.77	0.68	0.89	2.80	0.16
He 2020	26	2	8	46	0.76 [0.59, 0.89]	0.96 [0.86, 0.99]	0.88	0.93	0.85	18.35	0.25
Long 2020	35	0*	1	51	0.97 [0.85, 1.00]	1.00 [0.93, 1.00]	0.99	1	0.98	Not estimable	0.03
Ma 2020	43	26	7	82	0.86 [0.73, 0.94]	0.76 [0.67, 0.84]	0.79	0.62	0.92	3.57	0.18
Xie 2020	160	0*	7	0	0.96 [0.92, 0.98]	Not estimable	0.96	1	0	Not estimable	Not estimable
Mean values					0.92	0.70	0.85	0.81	0.91	5.64	0.14

Table 3. The performance of CT scan for COVID-19 infection. * Assumes no false positive due to non-reported data.

Key TP: True Positive, FP: False Positive, FN: False Negative, TN: True Negative, CI: Confidence Interval, PPV: Positive Predictive Value, NPV: Negative Predictive Value, PLR: Positive Likelihood Ratio, NLR: Negative Likelihood Ratio.

Study ID	Number of Patients with Positive PCR but Negative CT Scan ÷ Total Number of PCR Positive Patients (%)	Number of patients with CT changes from population with initial negative PCR that then became PCR positive later ÷ Number of patients with initial negative but then positive PCR later (%)
Ai 2020	21/601 (3.5%)	10/15 (67%)
Caruso 2020	2/62 (3.2%)	NR
Fang 2020	1/36 (2.8%)	NR
Gietema 2020	9/83 (10.8%)	NR/7
He 2020	8/27 (29.6%)	NR
Long 2020	1/30 (3.3%)	6/6 (100%)
Ma 2020	7/50 (14%)	NR/5
Xie 2020	7/162 (4.3%)	5/5 (100%)
Totals	56/1051 (5.3%)	21/26 (81%)

Table 4. Additional data. Column 1 shows the % of PCR positive patients who have a negative CT scan. Column 2 shows the proportion of patients with a CT scan suggestive of COVID-19 in patients who initially had a negative PCR, but then later had a positive PCR.

Key NR: Not Reported

Study (Year)	Selection (out of 4)	Comparability (out of 2)	Exposure (out of 3)
Ai et al. (2020)	****	*	**
Caruso et al. (2020)	****	*	**
Fang et al. (2020)	***	*	**
Gietema et al. (2020)	****	*	***
He et al. (2020)	***	*	**
Long et al. (2020)	****	*	**
Ma et al. (2020)	****	*	***
Xie et al. (2020)	***	*	***

Table 5. Newcastle-Ottawa Scale to Assess the Quality of Non-Randomised Studies.

Figure 1: Prisma Flow Diagram. The PRISMA diagram details the search and selection processes applied during the overview. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

Figure 2: Forest Plot of Chest CT vs. RT-PCR – Sensitivity and Specificity for the identification of COVID-19 cases.

Key CT: Computed Tomography, RT-PCR: Reverse Transcription Polymerase Chain Reaction, COVID-19: Coronavirus Disease 2019.

Figure 3: Summary Receiver Operator Characteristic (sROC) curves comparing the performance of Chest CT versus RT-PCR in the initial diagnosis of COVID-19.
Key CT: Computed Tomography, RT-PCR: Reverse Transcription Polymerase Chain Reaction.

Figure 4: Forest Plot of Chest CT vs. RT-PCR – Accuracy for identification and exclusion of COVID-19 cases.

Key CT: Computed Tomography, RT-PCR: Reverse Transcription Polymerase Chain Reaction, COVID-19: Coronavirus Disease 2019.

Figure 5: Forest Plot of Chest CT vs. RT-PCR – Accuracy for identification and exclusion of COVID-19 cases – Subgroup Analysis of China vs. Europe Based Studies.

Key CT: Computed Tomography, RT-PCR: Reverse Transcription Polymerase Chain Reaction, COVID-19: Coronavirus Disease 2019.

Figure 6: Forest Plot of Chest CT vs. RT-PCR – Accuracy for identification and exclusion of COVID-19 cases – Subgroup Analysis of Larger vs. Smaller Studies.

Key CT: Computed Tomography, RT-PCR: Reverse Transcription Polymerase Chain Reaction, COVID-19: Coronavirus Disease 2019.

Figure 7: Forest Plot of Chest CT vs. RT-PCR – Accuracy for identification and exclusion of COVID-19 cases – Subgroup Analysis of Adults or Mixed Age vs. Children Only Studies.

Key CT: Computed Tomography, RT-PCR: Reverse Transcription Polymerase Chain Reaction, COVID-19: Coronavirus Disease 2019.